Bromhexin, tablets 8 mg 20 pcs

Pharmacodynamics

Bromhexin has mucolytic (secretolytic) and expectorant (secretomotor) effects as well as a mild anti-cough effect. It reduces the viscosity of sputum, activates the permeable epithelium, increases the volume of sputum and improves its discharge. Stimulates the production of endogenous surfactant, which ensures the stability of alveolar cells during breathing. The effect is seen in 2-5 days after the start of treatment.

Pharmacokinetics

In oral administration, it is almost completely (99%) absorbed in the gastrointestinal tract (GIT) within 30 minutes. Bioavailability is about 80%. Binds to plasma proteins by 99%. It penetrates through placental and blood-brain barrier. It penetrates into breast milk. It undergoes demethylation and oxidation in the liver; it is metabolized to ambroxol. The elimination half-life is 15 hours (due to slow reverse diffusion from tissues). It is excreted by the kidneys as metabolites. In chronic renal failure (CKD), excretion of metabolites is impaired. With repeated use it may cumulate.

Indications

Acute and chronic bronchopulmonary diseases accompanied by the formation of high-viscosity sputum (bronchial asthma, pneumonia, tracheobronchitis, obstructive bronchitis, bronchiectasis, pulmonary emphysema, cystic fibrosis, tuberculosis, pneumoconiosis).

Pharmacological effect

Pharmacodynamics

Bromhexine has a mucolytic (secretolytic) and expectorant (secretomotor) effect, as well as a weak antitussive effect. Reduces the viscosity of sputum, activates the ciliated epithelium, increases the volume of sputum and improves its discharge. Stimulates the production of endogenous surfactant, which ensures the stability of alveolar cells during respiration. The effect appears within 2-5 days from the start of treatment.

Pharmacokinetics

When taken orally, it is almost completely (99%) absorbed from the gastrointestinal tract (GIT) within 30 minutes. Bioavailability is about 80%. Binds to plasma proteins by 99%. Penetrates through the placental and blood-brain barriers. Passes into breast milk. In the liver it undergoes demethylation and oxidation, metabolized to ambroxol. The half-life is 15 hours (due to slow reverse diffusion from tissues). Excreted by the kidneys in the form of metabolites. In chronic renal failure (CRF), the release of metabolites is impaired. May accumulate with repeated use.

Special instructions

In cases of impaired bronchial motility or with a significant volume of sputum secretion, the use of the drug Bromhexine requires caution due to the risk of retention of secretions in the respiratory tract.

During treatment, it is recommended to consume a sufficient amount of fluid, which increases the secretolytic effect of bromhexine.

In severe renal failure, it is necessary to take into account the possibility of accumulation of metabolites formed in the liver.

In children, treatment should be combined with postural drainage or vibration massage of the chest, which facilitates the removal of secretions from the bronchi.

The effect of the drug on the ability to drive vehicles and operate machinery

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Bromhexine

Composition

1 tablet contains:
active ingredient: bromhexine hydrochloride – 8 mg.

Contraindications

hypersensitivity to bromhexine and other components of the drug;

lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

peptic ulcer of the stomach and duodenum (in the acute stage);

pregnancy (first trimester);

children under 3 years of age.

With caution

renal and/or liver failure;

in case of impaired bronchial motility, accompanied by excessive accumulation of secretions;

with a history of tendency to gastric bleeding.

Side Effects

Digestive system disorders:

Uncommon: nausea, vomiting, diarrhea, abdominal pain;

Immune system disorders:

Uncommon: fever, hypersensitivity reactions (skin rash, angioedema, respiratory failure, itching, urticaria);

Very rare: anaphylactic reactions up to shock.

Disorders of the skin and subcutaneous tissues:

Very rare: Stevens-Johnson syndrome.

If side effects occur, stop taking the drug and consult a doctor.

Interaction

Bromhexine can be prescribed simultaneously with other drugs used in the treatment of bronchopulmonary diseases.

With the combined use of the drug Bromhexine and antitussives that suppress the cough reflex (including those containing codeine), due to a weakening of the cough reflex, there may be a risk of congestion.

Bromhexine promotes the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline, ampicillin, amoxicillin) into the lung tissue.

Overdose

Symptoms: nausea, vomiting and other gastrointestinal disorders.

Treatment: there is no specific antidote. In case of overdose, it is necessary to induce vomiting, and then give the patient liquid (milk or water). Gastric lavage is recommended within 1-2 hours after taking the drug.

Storage conditions

At a temperature not higher than 25 oC.

Manufacturer

Ozon, Russia